E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Coronary Microvascular Dysfunction (CMD). In CMD, ischemia is caused by impaired endothelial and/or non-endothelial coronary vasoreactivity resulting in the coronary microvasculature not dilating properly or becoming vasospastic. |
|
E.1.1.1 | Medical condition in easily understood language |
In coronary microvascular dysfunction (CMD), the small vessels that provide blood and oxygen to the heart muscle do not function properly. In some cases they cannot relax, in other cases they spasm. |
Bij patiënten met CMD functioneren de kleine kransslagaders die de hartspier van bloed voorzien niet goed. Soms kunnen de vaten zich niet goed ontspannen, of soms verkrampen ze juist. |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the effect of diltiazem on coronary microvascular function in patients with chronic angina and evidence of coronary microvascular dysfunction. |
|
E.2.2 | Secondary objectives of the trial |
To assess the effect of 6 weeks of treatment with diltiazem on the individual coronary function parameters in patients with coronary microvascular dysfunction.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Patients above the age of 18. 2. Patients with chronic angina, defined as symptoms of angina at least 2 times a week despite medical therapy for the last 3 months. 3. No signs of obstructive coronary artery disease (CAD), documented within 5 years* before inclusion by one of the following modalities: a. Coronary angiography: patients with non-obstructive (<50% stenosis) coronary arteries are eligible, or patients with intermediate stenosis (between 50 and 70%) with documented FFR >0.80 or iFR >0.89 on angiogram. In patients with a history of stenting are eligible if they have no current significant coronary epicardial stenoses, a minimum diameter stenosis of <10% is required. b. Coronary computed tomography angiography (CCTA) with finding of non-obstructive coronary arteries 4. Baseline coronary functiontesting with at least one of the following: a. CFR ≤ 2.0 b. IMR ≥ 25 c. Abnormal acetylcholine test defined as the presence of (recognizable) angina, ischemic ECG abnormalities with or without epicardial spasm 5. Signed written informed consent |
|
E.4 | Principal exclusion criteria |
1. Other cause of angina deemed highly likely by the treating physician. 2. Active use of calcium channel blockers or any use of calcium channel blockers in the previous two weeks or known intolerance for non-dihydropyridine calcium channel blockers. 3. Left ventricular ejection fraction < 50%. 4. Recent PCI within the past 3 months. 5. Patients with history of coronary artery bypass grafting (CABG). 6. Surgically uncorrected significant congenital or valvular heart disease, cardiomyopathy or myocarditis. 7. Significant renal impairment (eGFR < 30). 8. Significant hepatic impairment (history or cirrhosis or abnormal serum ALT or AST 3-fold greater than the upper limit of normal). 9. Pregnant women or women of child bearing potential who are planning to become pregnant within the next 3 months. 10. Prior non-cardiac illness with an estimated life expectancy < 1 year. 11. Contra-indication to coronary function testing: a. Contraindication or known hypersensitivity to adenosine. b. Contraindication or known hypersensitivity to acetylcholine. c. Contraindication to aminophylline. d. Ongoing dipyridamole treatment. 12. Contra-indication for treatment with CCB: second or third degree AV block, sinus node dysfunction and/or bradycardia (heart rate < 40 beats/minute) 13. Symptomatic hypotension or systolic BP < 100 mmHg at screening visit on 2 consecutive measurements. 14. History of hospitalization for asthma and/or current use of ≥ 2 types of pulmonary medications for asthma and/or severe COPD with FEV1 < 50% of predicted. 15.Participation in another clinical study with an IMP during the last month prior to enrolment. 16. Inability of the patient, in the opinion of the investigator, to understand and/or comply with study medications, procedures and/or follow-up OR any conditions that, in the opinion of the investigator, may render the patient unable to complete the study. 17. Unable to give informed consent (i.e. due to language barrier).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The proportion of patients having a successful treatment with diltiazem, defined as normalization of at least one abnormal parameter A normal IMR is specified as IMR < 25, a normal CFR being a CFR > 2 and a normal acetylcholine test is specified as one without ECG abnormalities and without (recognizable) angina signs of spasm at the same acetylcholine dose used at baseline. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
after 6 weeks of treatment with the IMP |
|
E.5.2 | Secondary end point(s) |
Change in the different parameters of the coronary function test (change in IMR, CFR, acetylcholine test parameters and absolute coronary blood flow). |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
After 6 weeks of treatment with the IMP |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Yes |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 4 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study may be terminated if the study procedures are not being performed according to GCP and/or if patients are placed at undue risk because of clinically relevant findings. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 5 |